Development of the new molecules and successful FDA drug approvals for cystic fibrosis treatment, are pushing the cystic fibrosis market growth

Pune, India, 2023/ Market Research Future (MRFR) has published a cooked research report on the “Global Cystic Fibrosis Market” that contains information from 2023 to 2030. 

Key Highlights on Cystic Fibrosis Market:

Global Cystic Fibrosis Market is accounted to register a CAGR of 13.50% during the forecast period and is estimated to reach USD 12.9 Billion by 2030.

Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system. It is caused by a mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which leads to the production of defective CFTR proteins. These proteins are responsible for maintaining the balance of salt and water in the body's cells, particularly in the lungs and digestive tract. In CF, the defective CFTR proteins result in the production of thick and sticky mucus that clogs the airways, making breathing difficult and increasing the risk of lung infections. The abnormal mucus also affects the pancreas, preventing the release of digestive enzymes necessary for proper nutrient absorption. As a chronic and progressive condition, CF requires ongoing medical management to alleviate symptoms, prevent complications, and improve the quality of life for individuals affected by the disease.

Key Players

MRFR recognizes the following companies as the key players in the Global Cystic Fibrosis Market— Allergan PLC, Chiesi Farmaceutici SpA, AbbVie, Hoffmann-La Roche AG, Gilead Sciences, PTC Therapeutics, Novartis AG, Vertex Pharmaceuticals Incorporated, and Pharmaxis Ltd.

Segment Analysis

The Global Cystic Fibrosis Market has been segmented based on Treatment Method, Route of Administration, and Drug Class.

Based on the Treatment Method, the market is segmented into Medication and Devices. The Medication category dominates the Cystic Fibrosis market due to its crucial role in managing symptoms, improving lung function, and enhancing the overall quality of life for individuals with CF.

Based on the Route of Administration, the market is segmented into Oral and Inhaled. The Oral category dominates the Cystic Fibrosis market due to its convenience, ease of administration, and potential for improved patient adherence to treatment regimens.

Based on Drug Class, the market is segmented into Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, Antibiotics, and CFTR modulators. The Pancreatic Enzyme Supplements category dominates the Cystic Fibrosis market due to its essential role in aiding digestion, improving nutrient absorption, and managing pancreatic insufficiency in individuals with CF.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cystic Fibrosis Market Research Report

Regional Analysis

The Global Cystic Fibrosis Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Cystic Fibrosis Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Cystic Fibrosis Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global Cystic Fibrosis Market comprises of Middle East, Africa, and Latin America.

In 2022, the cystic fibrosis market in North America recorded a valuation of USD 2.4 billion, capturing a substantial market share of approximately 45.80%. The region is projected to demonstrate noteworthy growth with a significant compound annual growth rate (CAGR) during the study period. The region's leading contribution to the study can be attributed to the increasing prevalence of cystic fibrosis and the availability of diverse treatment options. The expansion of the regional market will be further propelled by augmented investment in research and development efforts focused on CF medications, as well as favorable government initiatives aimed at enhancing patient outcomes in this field.

Key Findings of the Study

• The Global Cystic Fibrosis Market is expected to reach USD 12.9 Billion by 2030, at a CAGR of 13.50% during the forecast period.


• North America recorded a revenue of USD 2.4 billion, capturing a market share of approximately 45.80%. This region is projected to experience noteworthy growth at a significant compound annual growth rate (CAGR) throughout the study period. The substantial contribution of North America to the study results from the increasing prevalence of cystic fibrosis and the availability of a diverse range of treatment options.


• Based on the Treatment Method, the Market has been segmented into Medication holding the largest market in 2023.


• Allergan PLC, Chiesi Farmaceutici SpA, AbbVie, Hoffmann-La Roche AG, Gilead Sciences, PTC Therapeutics, Novartis AG, Vertex Pharmaceuticals Incorporated, and Pharmaxis Ltd.